n.a. (NEOP)

0.00
OTC BB
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange OTC BB
Shares Outstanding 3.00M
Div & Yield N.A. (N.A)
Neoprobe To Present At Cowen And Company 31st Annual Health Care Conference

Neoprobe To Present At Cowen And Company 31st Annual Health Care Conference

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Phase 2 Lymphoseek® (Tilmanocept) Data Published Online In Annals Of Surgical Oncology

Phase 2 Lymphoseek® (Tilmanocept) Data Published Online In Annals Of Surgical Oncology

Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that results from a Phase II study of Lymphoseek ® (Tilmanocept) have been published...

BIO CEO Conference Live Blog: Day 2

BIO CEO Conference Live Blog: Day 2

TheStreet's Adam Feuerstein blogs a conference in New York for smaller biotechs.

Neoprobe’s Phase 3 Lymphoseek Study Reaches Accrual Goal

Neoprobe’s Phase 3 Lymphoseek Study Reaches Accrual Goal

Neoprobe Corporation (NYSE: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that a multi-center Phase 3 study of Lymphoseek ® has enrolled clinical subjects...

Neoprobe To Present Lymph Node Product Updates At BIO CEO Conference

Neoprobe To Present Lymph Node Product Updates At BIO CEO Conference

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present a business...

Neoprobe Common Stock Approved For Listing On NYSE Amex

Neoprobe Common Stock Approved For Listing On NYSE Amex

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its common stock has been cleared for listing on the NYSE Amex.

Neoprobe To Present At OneMedForum

Neoprobe To Present At OneMedForum

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr.

Neoprobe Hosted Analyst Day In NYC

Neoprobe Hosted Analyst Day In NYC

At its first Analyst Day, Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, provided analysts and investors in attendance with an in-depth update on...

Neoprobe Granted Pre-IND Meeting With FDA To Review RIGS Technology

Neoprobe Granted Pre-IND Meeting With FDA To Review RIGS Technology

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has requested and been granted a Type B pre-IND meeting with the U.

Lymphoseek Data Presented At International Sentinel Node Society Annual Meeting

Lymphoseek Data Presented At International Sentinel Node Society Annual Meeting

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that investigators are presenting data and insights on Lymphoseek ® use in lymph...

Neoprobe Names Executive Vice President, Chief Development Officer

Neoprobe Names Executive Vice President, Chief Development Officer

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced today that Dr.

Neoprobe Announces Third Quarter 2010 Results

Neoprobe Announces Third Quarter 2010 Results

Neoprobe Corporation (OTCBB: NEOP - News), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the third quarter of 2010 and for the nine-month...

Neoprobe 3rd Quarter Business Update Conference Call Invitation

Neoprobe 3rd Quarter Business Update Conference Call Invitation

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today confirmed that it would report its financial results for the third quarter of 2010 on...

Neoprobe Announces $6 Million Capital Investment

Neoprobe Announces $6 Million Capital Investment

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has entered into agreements with institutional investors for a registered...

Neoprobe To Present At LifeTech Capital 1st Annual Miami Medical Investors Conference

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its Senior Vice President and CFO, Brent Larson, will present at the...

Neoprobe Awarded Grant From Qualifying Therapeutic Discovery Project Program

Neoprobe Awarded Grant From Qualifying Therapeutic Discovery Project Program

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has been awarded a grant of $244,479 under the qualifying therapeutic...

Neoprobe Files Response To FDA Review Letter Of RIGScan™ Biologic License Application

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has submitted a response letter to the U.

Neoprobe To Present At Newsmakers In The Biotech Industry Conference

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and CEO, David Bupp, will present at the upcoming Newsmakers in...

Neoprobe Completes Lymphoseek Pre-NDA Meeting

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a pre-NDA assessment for Lymphoseek ® with the U.

TriPoint Global Research Publishes Research Report With Market Outperform Rating On Neoprobe Corp. (NEOP)

TriPoint Global Research Publishes Research Report With Market Outperform Rating On Neoprobe Corp. (NEOP)

First graph of release should read: TriPoint Global Research publishes a Research Report on Neoprobe Corp.

Rodman Rambles: Promising Biotechs

Rodman Rambles: Promising Biotechs

This week's Rodman investor confab included some small, early biotechs worthy of investor attention.

Neoprobe Presents Lymphoseek Data At International TERACHEM Symposium

Neoprobe Presents Lymphoseek Data At International TERACHEM Symposium

Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Senior Vice President of Pharmaceutical Research and Clinical Development,...

Neoprobe To Present At Upcoming Investor Conferences

Neoprobe To Present At Upcoming Investor Conferences

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, is planning to provide business and pipeline updates to the investor community at a series of...

Neoprobe Announces Second Quarter 2010 Results

Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2010 and for the six-month period ended...

Neoprobe To Report Second Quarter 2010 Results

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and surgical diagnostic and treatment products, today announced that the Company will report financial results for the second quarter...

Neoprobe Initiates Application For Listing On NYSE: AMEX

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced today it has initiated the application process for listing on the NYSE: AMEX stock exchange.

Neoprobe Reports Organizational Developments

Neoprobe Reports Organizational Developments

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced today that the Company’s Board of Directors has elected a Vice Chairman, approved the...

Neoprobe Announces 2010 Annual Meeting Results

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its ...

Neoprobe Announces Preliminary Second Quarter 2010 Revenue

Neoprobe Announces Preliminary Second Quarter 2010 Revenue

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it expects to report revenue of approximately $2.

Neoprobe Completes CMC Data Review For Lymphoseek®

Neoprobe Completes CMC Data Review For Lymphoseek®

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it had successfully completed the preliminary review of information to be...